These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15557950)

  • 1. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus.
    Vij R; Triadafilopoulos G; Owens DK; Kunz P; Sanders GD
    Gastrointest Endosc; 2004 Nov; 60(5):739-56. PubMed ID: 15557950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia.
    Hur C; Nishioka NS; Gazelle GS
    Dig Dis Sci; 2003 Jul; 48(7):1273-83. PubMed ID: 12870783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
    Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
    Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A guide for surveillance of patients with Barrett's esophagus.
    Provenzale D; Kemp JA; Arora S; Wong JB
    Am J Gastroenterol; 1994 May; 89(5):670-80. PubMed ID: 8172136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
    Gerson LB; Groeneveld PW; Triadafilopoulos G
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis.
    Comay D; Blackhouse G; Goeree R; Armstrong D; Marshall JK
    Can J Gastroenterol; 2007 Apr; 21(4):217-22. PubMed ID: 17431509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness, safety, and cost-effectiveness of photodynamic therapy in Barrett's esophagus: a systematic review.
    Sánchez A; Reza M; Blasco JA; Callejo D
    Dis Esophagus; 2010 Nov; 23(8):633-40. PubMed ID: 20545970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
    Hur C; Choi SE; Rubenstein JH; Kong CY; Nishioka NS; Provenzale DT; Inadomi JM
    Gastroenterology; 2012 Sep; 143(3):567-575. PubMed ID: 22626608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
    Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
    Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resection for Barrett's mucosa with high-grade dysplasia: implications for prophylactic photodynamic therapy.
    Ferguson MK; Naunheim KS
    J Thorac Cardiovasc Surg; 1997 Nov; 114(5):824-9. PubMed ID: 9375613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
    Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Barrett's esophagus with high-grade dysplasia.
    McAllaster JD; Buckles D; Al-Kasspooles M
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):303-16. PubMed ID: 19275509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-utility analysis of ablative therapy for Barrett's esophagus.
    Inadomi JM; Somsouk M; Madanick RD; Thomas JP; Shaheen NJ
    Gastroenterology; 2009 Jun; 136(7):2101-2114.e1-6. PubMed ID: 19272389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrett's oesophagus: a review of costs of the illness.
    Arguedas MR; Eloubeidi MA
    Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis.
    Pohl H; Sonnenberg A; Strobel S; Eckardt A; Rösch T
    Gastrointest Endosc; 2009 Oct; 70(4):623-31. PubMed ID: 19394011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett's esophagus.
    Filby A; Taylor M; Lipman G; Lovat L; Haidry R
    J Comp Eff Res; 2017 Jul; 6(5):425-436. PubMed ID: 28541099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus.
    Boger PC; Turner D; Roderick P; Patel P
    Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1332-42. PubMed ID: 21050235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient preferences for the management of high-grade dysplasia in Barrett's esophagus.
    Hur C; Wittenberg E; Nishioka NS; Gazelle GS
    Dig Dis Sci; 2005 Jan; 50(1):116-25. PubMed ID: 15712648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.